UA92494C2 - Производные пиррола как положительные аллостерические модуляторы метаботропных глутаматных рецепторов - Google Patents

Производные пиррола как положительные аллостерические модуляторы метаботропных глутаматных рецепторов

Info

Publication number
UA92494C2
UA92494C2 UAA200714061A UAA200714061A UA92494C2 UA 92494 C2 UA92494 C2 UA 92494C2 UA A200714061 A UAA200714061 A UA A200714061A UA A200714061 A UAA200714061 A UA A200714061A UA 92494 C2 UA92494 C2 UA 92494C2
Authority
UA
Ukraine
Prior art keywords
nrc
formula
receptors
allosteric modulators
positive allosteric
Prior art date
Application number
UAA200714061A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Стефания Гаглиарди
Пул Эманюэл Льо
Лейн Лингард
Джованни Паломби
Соня Мария Поли
Жан-Филип Роше
Original Assignee
Аддекс Фарма Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аддекс Фарма Са filed Critical Аддекс Фарма Са
Publication of UA92494C2 publication Critical patent/UA92494C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fats And Perfumes (AREA)
UAA200714061A 2005-05-18 2006-05-17 Производные пиррола как положительные аллостерические модуляторы метаботропных глутаматных рецепторов UA92494C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0510141.5A GB0510141D0 (en) 2005-05-18 2005-05-18 Novel compounds B3

Publications (1)

Publication Number Publication Date
UA92494C2 true UA92494C2 (ru) 2010-11-10

Family

ID=34708379

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200714061A UA92494C2 (ru) 2005-05-18 2006-05-17 Производные пиррола как положительные аллостерические модуляторы метаботропных глутаматных рецепторов

Country Status (23)

Country Link
US (1) US20090203737A1 (enExample)
EP (1) EP1912979B1 (enExample)
JP (2) JP2008540637A (enExample)
KR (1) KR20080014046A (enExample)
CN (1) CN101218234B (enExample)
AT (1) ATE513828T1 (enExample)
AU (1) AU2006248657B2 (enExample)
BR (1) BRPI0610059A2 (enExample)
CA (1) CA2608324A1 (enExample)
CY (1) CY1111859T1 (enExample)
DK (1) DK1912979T3 (enExample)
EA (1) EA014081B1 (enExample)
ES (1) ES2367663T3 (enExample)
GB (1) GB0510141D0 (enExample)
IL (1) IL187187A0 (enExample)
MX (1) MX2007014403A (enExample)
NO (1) NO20076480L (enExample)
NZ (1) NZ564202A (enExample)
PL (1) PL1912979T3 (enExample)
PT (1) PT1912979E (enExample)
UA (1) UA92494C2 (enExample)
WO (1) WO2006123257A2 (enExample)
ZA (1) ZA200710279B (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080027463A (ko) * 2005-05-18 2008-03-27 아덱스 파마 에스에이 대사성 글루타메이트 수용체의 양성 알로스테릭조절자로서의 치환된 옥사디아졸 유도체
GB0510139D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0510140D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B2
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
GB0622202D0 (en) * 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds
EA201070143A1 (ru) 2007-07-13 2010-08-30 Аддекс Фарма С.А. Новые гетероароматические производные и их использование в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
CN101801954B (zh) 2007-09-20 2013-10-09 Irm责任有限公司 作为gpr119活性调节剂的化合物和组合物
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US20100317630A1 (en) * 2009-02-04 2010-12-16 Recordati Ireland Limited Novel heterocyclic compounds as mglu5 antagonists
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
WO2010124055A1 (en) * 2009-04-23 2010-10-28 Merck Sharp & Dohme Corp. 2-alkyl piperidine mglur5 receptor modulators
GB0912946D0 (en) * 2009-07-24 2009-09-02 Addex Pharmaceuticals Sa New compounds 5
US8772301B2 (en) 2009-12-18 2014-07-08 Sunovion Pharmaceuticals, Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
EP2566853B1 (en) 2010-05-05 2017-01-25 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
SG10201913053QA (en) 2011-05-13 2020-03-30 Array Biopharma Inc Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
PH12014500355A1 (en) 2011-08-15 2014-03-31 Intermune Inc Lysophosphatidic acid receptor antagonists
SG11201402660YA (en) 2011-12-21 2014-10-30 Novira Therapeutics Inc Hepatitis b antiviral agents
SG10201605291WA (en) 2012-08-28 2016-08-30 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
RS55593B1 (sr) 2012-11-13 2017-06-30 Array Biopharma Inc Jedinjenja biciklične uree, tiouree, guanidina i cijanoguanidina korisna za lečenje bola
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
SMT201800169T1 (it) 2012-11-13 2018-05-02 Array Biopharma Inc Composti di n-pirrolidinile, n'-pirazolile-urea, tiourea, guanidina e cianoguanidina come inibitore di chinasi trka
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078408A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
PT2961732T (pt) 2013-02-28 2017-06-26 Janssen Sciences Ireland Uc Sulfamoil-arilamidas e utilização das mesmas como medicamentos para o tratamento de hepatite b
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
MX353412B (es) 2013-04-03 2018-01-10 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
LT3024819T (lt) 2013-07-25 2018-06-11 Janssen Sciences Ireland Uc Pirolamido dariniai, turintys glioksamido pakaitų, ir jų panaudojimas kaip vaistų hepatito b gydymui
NZ717629A (en) 2013-10-23 2021-12-24 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US20150216938A1 (en) 2014-02-05 2015-08-06 Novira Therapeutics Inc. Combination therapy for treatment of hbv infections
DK3102572T3 (en) 2014-02-06 2019-02-04 Janssen Sciences Ireland Uc SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
EP3154959B1 (en) 2014-05-15 2019-07-10 Array Biopharma, Inc. 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
HK1247147A1 (zh) 2015-03-19 2018-09-21 诺维拉治疗公司 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
AR106192A1 (es) 2015-09-29 2017-12-20 Novira Therapeutics Inc Formas cristalinas de un agente antiviral contra la hepatitis b
WO2017181141A2 (en) 2016-04-15 2017-10-19 Novira Therapeutics, Inc. Combinations and methods comprising a capsid assembly inhibitor
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
WO2019175657A1 (en) 2018-03-14 2019-09-19 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
EP3781556B1 (en) 2018-04-19 2025-06-18 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CN118221646A (zh) 2018-07-13 2024-06-21 吉利德科学公司 Pd-1/pd-l1抑制剂
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
KR102635333B1 (ko) 2018-10-24 2024-02-15 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020154431A1 (en) * 2019-01-25 2020-07-30 Lynch Kevin R Inhibitors of spinster homolog 2 (spns2) for use in therapy
MX2021010145A (es) 2019-02-22 2021-09-14 Janssen Sciences Ireland Unlimited Co Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
JP2022532526A (ja) 2019-05-06 2022-07-15 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｈｂｖ感染又はｈｂｖ誘導性疾患の処置において有用なアミド誘導体
MX2022006865A (es) 2019-12-06 2022-07-11 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
AU2020417293A1 (en) 2020-01-03 2022-09-01 Berg Llc Polycyclic amides as UBE2K modulators for treating cancer
WO2022069953A1 (en) * 2020-09-29 2022-04-07 Ranjith Siddaraj Synthesis and characterization of (s)-3-(5- fluoropyridin-2-yl)-5-(piperidin-3-yl)-l,2,4-oxadiazole derivatives and their secretory phospholipase a2 (spla2) inhibitor activity
DK4347031T3 (da) 2021-06-04 2025-12-01 Vertex Pharma N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler
WO2024059207A2 (en) * 2022-09-15 2024-03-21 Vanderbilt University Pyrazoloether analogs as mglu5 negative allosteric modulators and methods of making and using the same

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3509153A (en) * 1967-03-24 1970-04-28 Miles Lab 5-phenyl (or 5-phenylalkyl)-2-(omega-(4-phenyl-1-piperazinyl)alkyl)tetrazoles
US3991064A (en) * 1975-01-17 1976-11-09 Warner-Lambert Company Benzonaphthyridines
US3966748A (en) * 1975-05-08 1976-06-29 American Cyanamid Company Para-fluorophenyl-N-heterocyclic substituted butanes
US5338969A (en) * 1991-06-27 1994-08-16 Texas Instruments, Incorporated Unerasable programmable read-only memory
US6846839B1 (en) * 1995-06-07 2005-01-25 Sugen, Inc. Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
GB9603755D0 (en) * 1996-02-22 1996-04-24 Pfizer Ltd Therapeutic agents
US6437146B1 (en) * 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
US7217714B1 (en) * 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
WO2000066578A1 (en) * 1999-04-30 2000-11-09 Pfizer Products Inc. Compounds for the treatment of obesity
CA2393821C (en) * 1999-12-16 2009-05-26 Schering Corporation Substituted imidazole neuropeptide y y5 receptor antagonists
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
KR100850728B1 (ko) * 2000-06-12 2008-08-06 에자이 알앤드디 매니지먼트 가부시키가이샤 1,2-디하이드로피리딘 화합물, 그의 제조 방법 및 그의 용도
DE60110066T2 (de) * 2000-06-16 2006-02-02 Smithkline Beecham P.L.C., Brentford Piperidine zur verwendung als orexinrezeptorantagonisten
US6894063B2 (en) * 2000-09-14 2005-05-17 Schering Corporation Substituted urea neuropeptide Y Y5 Receptor antagonists
US6946476B2 (en) * 2000-12-21 2005-09-20 Schering Corporation Heteroaryl urea neuropeptide Y Y5 receptor antagonists
IL160701A0 (en) * 2001-09-21 2004-08-31 Mitsubishi Pharma Corp 3-substituted-4-pyrimidone derivatives
MXPA04002662A (es) * 2001-09-21 2004-11-22 Sanofi Aventis Derivados de 3-substituida-4-pirimidona.
ATE396186T1 (de) * 2001-10-04 2008-06-15 Merck & Co Inc Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5
WO2003037862A1 (en) * 2001-10-30 2003-05-08 Nippon Shinyaku Co., Ltd. Amide derivatives and drugs
US6806279B2 (en) * 2001-12-17 2004-10-19 Sunesis Pharmaceuticals, Inc. Small-molecule inhibitors of interleukin-2
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
WO2003093236A1 (en) * 2002-05-02 2003-11-13 Euro-Celtique, S.A. 1-(pyrid-2-yl)-piperazine compounds as metabotropic glutamate receptor inhibitor
JP4901102B2 (ja) * 2002-05-03 2012-03-21 エクセリクシス， インク． プロテインキナーゼモジュレーターおよびその使用方法
AU2003264018A1 (en) * 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain
MXPA05005583A (es) * 2002-11-26 2005-07-27 Pfizer Prod Inc Activadores de ppar.
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
CN1856484B (zh) * 2003-07-24 2010-09-22 欧洲凯尔蒂克公司 用于治疗或预防疼痛的杂芳基-四氢吡啶基化合物
RU2357969C2 (ru) * 2003-08-25 2009-06-10 АДЕНОЗАЙН ТЕРАПЬЮТИКС, ЭлЭлСи Новые замещенные 8-гетероарилксантины и фармацевтическая композиция на их основе
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
FR2865733B1 (fr) * 2004-02-04 2007-10-12 Merck Sante Sas Derives de thiazolylimidazole, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en medecine
CA2567398A1 (en) * 2004-05-25 2005-12-08 Pfizer Products Inc. New use
CA2581179A1 (en) * 2004-09-29 2006-04-06 Mitsubishi Pharma Corporation 6-(pyridinyl)-4 pyrimidone derivatives as tau protein kinase 1 inhibitors
WO2006044509A2 (en) * 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
WO2006048771A1 (en) * 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510143D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
EP1810972B1 (en) * 2004-11-10 2012-01-25 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic compound and pharmaceutical use thereof
US7910561B2 (en) * 2004-12-15 2011-03-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
GB0510139D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0510140D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B2
KR20080027463A (ko) * 2005-05-18 2008-03-27 아덱스 파마 에스에이 대사성 글루타메이트 수용체의 양성 알로스테릭조절자로서의 치환된 옥사디아졸 유도체
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
GB0622202D0 (en) * 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds

Also Published As

Publication number Publication date
EP1912979B1 (en) 2011-06-22
AU2006248657B2 (en) 2012-07-19
MX2007014403A (es) 2008-04-21
US20090203737A1 (en) 2009-08-13
WO2006123257A2 (en) 2006-11-23
PT1912979E (pt) 2011-08-22
EA200702470A1 (ru) 2008-06-30
CN101218234B (zh) 2011-12-14
CA2608324A1 (en) 2006-11-23
IL187187A0 (en) 2008-02-09
WO2006123257A3 (en) 2007-05-03
CY1111859T1 (el) 2015-11-04
ES2367663T3 (es) 2011-11-07
AU2006248657A1 (en) 2006-11-23
CN101218234A (zh) 2008-07-09
PL1912979T3 (pl) 2011-11-30
ATE513828T1 (de) 2011-07-15
NZ564202A (en) 2011-04-29
JP2012184254A (ja) 2012-09-27
WO2006123257A8 (en) 2007-03-15
NO20076480L (no) 2008-01-28
DK1912979T3 (da) 2011-08-22
HK1112909A1 (en) 2008-09-19
GB0510141D0 (en) 2005-06-22
JP2008540637A (ja) 2008-11-20
EA014081B1 (ru) 2010-08-30
KR20080014046A (ko) 2008-02-13
BRPI0610059A2 (pt) 2010-05-25
ZA200710279B (en) 2009-03-25
EP1912979A2 (en) 2008-04-23

Similar Documents

Publication Publication Date Title
UA92494C2 (ru) Производные пиррола как положительные аллостерические модуляторы метаботропных глутаматных рецепторов
EA200901160A1 (ru) Производные 3-циано-4-(4-тетрагидропиранфенил)пиридин-2-она
WO2008056259A3 (en) Oxazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
SG155938A1 (en) Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors
MX2009009422A (es) Derivados de 3-ciano-piridona 1,4-disustituidos y su uso como moduladores del receptor mglur-2 positivo.
NO20083500L (no) 1,4-disubstituerte 3-cyano-pyridonderivater og deres anvendelse som positiv-allosteriske modulatorer av mGluR2 receptorer
MY152078A (en) 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
PH12012500690A1 (en) Positive allosteric modulators (pam)
EA200901159A1 (ru) Производные 3-циано-4-(4-фенилпиперидин-1-ил)пиридин-2-она
US6432958B1 (en) 2-piperazinoalkylaminobenzoazole derivatives: dopamine receptor subtype specific ligands
TW200718692A (en) Dihydrobenzofuran derivatives and uses thereof
MA30289B1 (fr) Dérivés d'amines
EA200700047A1 (ru) Новые алкильные производные в качестве метаботропных рецепторов глутамата
PH12012501773A1 (en) Arylethynyl derivatives
EA200501585A1 (ru) Производные азетидинкарбоксамида и их применение при лечении нарушений, опосредованных св1 рецепторами
EA200702471A1 (ru) Новые гетероциклические соединения в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
MX2010005753A (es) Derivados de isoxazolo-pirazina.
MA35133B1 (fr) Dérivés d'éthynyle comme modulateurs allostériques positifs de mglur5
ZA200600419B (en) Indol-6 sulfonamide derivatives, their preparation and their use as 5-HT-6 modulators
WO2007054444A3 (en) 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives
WO2000018767A9 (en) 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands
DE602004011914D1 (de) Benzimidazole derivate und ihre anwendung als gaba a rezeptor komplex modulatoren
SE0400440D0 (sv) Novel Cinnamic Amides
AU2008258664A8 (en) Prolinamide-tetrazole derivatives as NK3 receptor antagonists
UA99125C2 (ru) 1,4-замещенные 3-цианопиридонпроизводные и их применение в качестве положительных модуляторов mglur2-рецептора